Teladoc (TDOC) CEO Charles Divita Converts Awards, Sells 17,805 Shares

What Happened
Charles Divita, CEO of Teladoc Health (TDOC), converted restricted/performance stock units into common shares on Sept. 10, 2026 (3,642 and 39,160 shares shown as converted) and then sold 17,805 shares in an open-market transaction on Sept. 11, 2026 at $6.10 per share for total proceeds of $108,682. The filing also shows corresponding derivative dispositions for 3,642 and 39,160 shares at $0, which the filer says were used to satisfy tax withholding obligations.

Key Details

• Transaction types: conversion of awards (reported as "M") on 2026-09-10 and open-market sale ("S") on 2026-09-11.
• Sale: 17,805 shares at $6.10 = $108,682.
• Conversions reported: 3,642 shares and 39,160 shares converted to common stock on 2026-09-10. Corresponding dispositions of those same amounts are reported at $0 as tax withholding.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes of note:
  • F1/F2: Performance stock units (PSUs) and restricted stock units (RSUs) convert to TDOC common stock on a one-for-one basis.
  • F3: Shares were sold/withheld to cover tax withholding on vesting.
  • F4: The filing references PSUs earned on June 10, 2026 (23,591 PSUs) with a multi-step vesting schedule.
  • F5: The filing references a June 10, 2024 RSU grant (469,924 RSUs) with staged vesting.
• Timeliness: Form filed 2026-09-14 reporting transactions on 9/10 and 9/11 — filing appears to be within the normal 2-business-day Form 4 deadline.

Context

• These were not open-market purchases; they were conversions of equity awards (PSUs/RSUs) into shares, with some shares withheld/sold to cover taxes and a separate small open-market sale for cash.
• Conversions and tax-withholding disposals are routine for vesting awards and do not, by themselves, indicate the insider’s broader market view.